Skip to main navigation Skip to search Skip to main content

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study

  • Komal L. Jhaveri
  • , Elgene Lim
  • , Rinath Jeselsohn
  • , Cynthia X. Ma
  • , Erika P. Hamilton
  • , Cynthia Osborne
  • , Manali Bhave
  • , Peter A. Kaufman
  • , J. Thaddeus Beck
  • , Luis Manso Sanchez
  • , Ritesh Parajuli
  • , Hwei Chung Wang
  • , Jessica J. Tao
  • , Seock Ah Im
  • , Kathleen Harnden
  • , Kan Yonemori
  • , Ajay Dhakal
  • , Patrick Neven
  • , Philippe Aftimos
  • , Jean Yves Pierga
    • Yen Shen Lu, Timothy Larson, Yolanda Jerez, Kostandinos Sideras, Joohyuk Sohn, Sung Bae Kim, Cristina Saura, Aditya Bardia, Sarah L. Sammons, Francesca Bacchion, Yujia Li, Eunice Yuen, Shawn T. Estrem, Vanessa Rodrik-Outmezguine, Bastien Nguyen, Roohi Ismail-Khan, Lillian Smyth, Muralidhar Beeram

Research output: Contribution to journal › Article › peer-review

42   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science